01—Abstract
Summary
Summary of the 8-K filed November 2, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third-quarter 2026 financial results on November 2, 2026, with total revenues of $1,123 milliona, up 41% year-over-year from $795 million.
INGREZZA net product sales were $801 millionb (up 17%), CRENESSITY net product sales were $211 million (up 115%), and VYKAT XR net product sales were $107 million. The company said net product sales exceeded $1 billion for the first time. GAAP net income was $207 million ($1.96 diluted EPS) versus $210 million ($2.04) a year earlier, while non-GAAP net income was $347 million ($3.29 diluted EPS) versus $222 million ($2.17).
The company raised its full-year 2026 INGREZZA net product sales guidance to $2.90 to $2.925 billionc from $2.825 to $2.875 billion. Updated full-year guidance also lowered GAAP SG&A to $1.540 to $1.560 billion from $1.575 to $1.600 billion, and raised IPR&D to $34 million from $23 million; GAAP R&D guidance was unchanged. Results reflect the May 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR and about $2.2 billion of related intellectual property.
Cash, cash equivalents and marketable securities were approximately $790 milliond at September 30, 2026, compared with $2,543 million at December 31, 2025. Other developments include Phase 1 initiation for NBIP-'1968 (a GLP-1/GIP/glucagon triple agonist for obesity), a Phase 2 study of NBI-'567 for cognitive impairment in Alzheimer's disease, and the appointment of Eiry W. Roberts, M.D. as Chief Medical Officer.
The company will host an R&D Day in New York on December 15, 2026. The filing furnishes the earnings release under Item 2.02, which is not deemed filed for purposes of Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Total Q3 2026 revenues of $1,123 million, up 41% year-over-year from $795 million
- INGREZZA Q3 2026 net product sales of $801 million, up 17% year-over-year, with record TRx and NRx
- CRENESSITY Q3 2026 net product sales of $211 million, up 115% year-over-year
- VYKAT XR Q3 2026 net product sales of $107 million following the Soleno acquisition closed in May 2026
- Full-year 2026 INGREZZA net product sales guidance raised to $2.90–$2.925 billion from $2.825–$2.875 billion
- GAAP diluted EPS of $1.96 versus $2.04 a year earlier; non-GAAP diluted EPS of $3.29 versus $2.17
- Cash, cash equivalents and marketable securities of approximately $790 million at September 30, 2026, down from $2,543 million at December 31, 2025
03—Questions
Frequently Asked Questions
How did Neurocrine's revenue perform in the third quarter of 2026?
Total revenues were $1,123 million, compared with $795 million in the third quarter of 2025, a 41% increase. The company stated that net product sales exceeded $1 billion for the first time, driven by INGREZZA, CRENESSITY and VYKAT XR.
Why did GAAP net income decline while non-GAAP net income increased?
GAAP net income was $207 million versus $210 million a year earlier, and non-GAAP net income rose to $347 million from $222 million. The filing attributes the GAAP results to operating expenses tied to the Soleno acquisition, higher R&D and SG&A spending, and a $52 million loss from changes in fair values of equity investments, which the company excludes from non-GAAP results.
What changed in the full-year 2026 financial guidance?
INGREZZA net product sales guidance was raised to $2.90–$2.925 billion from $2.825–$2.875 billion. GAAP SG&A guidance was lowered to $1.540–$1.560 billion from $1.575–$1.600 billion, and IPR&D guidance increased to $34 million from $23 million. GAAP R&D and amortization of acquired intangible assets guidance were unchanged.
What was the impact of the Soleno Therapeutics acquisition?
The acquisition, which closed in May 2026, added VYKAT XR. The company recorded approximately $2.2 billion of intellectual property related to VYKAT XR, amortized over an expected 16 years, and approximately $168 million of VYKAT XR inventory fair value step-up. Acquisition-related costs and accelerated equity vesting for Soleno employees affected GAAP results.
What upcoming events and pipeline milestones did the company identify?
The company cited Phase 3 readouts expected for osavampator in major depressive disorder and direclidine in schizophrenia, and plans to host an R&D Day in New York on December 15, 2026. It also reported initiating a Phase 1 study of NBIP-'1968 and a Phase 2 study of NBI-'567 for cognitive impairment in Alzheimer's disease.
04—Continue